文献速递临床试验与 GCP流行病学与生物统计

辅助变量富集的生物标志物分层设计

Auxiliary variable-enriched biomarker-stratified design.
PubMed 文献 · Stat Med · 2018-09-16

针对精准医学试验中生物标志物分层设计成本高、效率低的问题,提出一种基于廉价辅助变量的富集设计(AEBSD),利用与真实生物标志物正相关的辅助变量进行富集。当真实标志物阳性率低且辅助变量阳性预测值高于该阳性率时,AEBSD可降低总试验成本,并允许筛选后立即随机化以缩短治疗等待时间。采用自适应贝叶斯方法在试验进行中调整假定阳性预测值,通过数值研究和实例验证。

要点

  • AEBSD利用廉价辅助变量富集,降低标志物分层设计的总成本。
  • 当真实标志物阳性率低且辅助变量PPV高于阳性率时,成本优势成立。
  • 筛选后无需等待真实标志物结果即可随机化,缩短治疗等待时间。

核心结论

  • 在真实生物标志物阳性率低且辅助变量阳性预测值高于该阳性率时,AEBSD较标准生物标志物分层设计降低总试验成本。

研究设计与样本

  • 提出辅助变量富集的生物标志物分层设计(AEBSD),基于与真实生物标志物正相关的廉价辅助变量进行富集。
  • 采用自适应贝叶斯方法在试验进行中调整假定的阳性预测值(PPV)。
  • 通过数值研究和实例说明方法,并提供R包。

主要发现

  • 当真实生物标志物阳性率低且辅助变量PPV大于该阳性率时,AEBSD较标准BSD降低总试验成本。
  • AEBSD可立即随机化筛选过程中选中的患者,无需等待真实生物标志物检测结果,从而缩短治疗等待时间。

临床怎么用

  • 在真实标志物阳性率低、辅助变量廉价且与真实标志物正相关时,可考虑采用AEBSD替代标准BSD以降低成本。
  • 利用辅助变量筛选后可立即随机化,有助于缩短患者治疗等待时间。
  • 试验进行中可采用自适应贝叶斯方法调整假定的PPV。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials in the era of precision medicine require assessment of biomarkers to identify appropriate subgroups of patients for targeted therapy. In a biomarker-stratified design (BSD), biomarkers are measured on all patients and used as stratification variables. However, such a trial can be both inefficient and costly, especially when the prevalence of the subgroup of primary interest is low and the cost of assessing the biomarkers is high. Efficiency can be improved and costs reduced by using enriched biomarker-stratified designs, in which patients of primary interest, typically the biomarker-positive patients, are oversampled. We consider a special type of enrichment design, an auxiliary variable-enriched design (AEBSD), in which enrichment is based on some inexpensive auxiliary variable that is positively correlated with the true biomarker. The proposed AEBSD reduces the total cost of the trial compared with a standard BSD when the prevalence rate of true biomarker positivity is small and the positive predictive value (PPV) of the auxiliary biomarker is larger than the prevalence rate. In addition, for an AEBSD, we can immediately randomize the patients selected in the screening process without waiting for the result of the true biomarker test, reducing the treatment waiting time. We propose an adaptive Bayesian method to adjust the assumed PPV while the trial is ongoing. Numerical studies and an example illustrate the approach. An R package is available.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Wang T, Wang X, Zhou H, et al. Auxiliary variable-enriched biomarker-stratified design. Stat Med. 2018. PMID: 30221368. doi:10.1002/sim.7938

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。